Table 1.
Characteristics of incidentally vs non-incidentally diagnosed cancer patients, and crude/adjusted ORs of incidental status (n=13 810)
| Total | Incidental | Crude | Adjusted* | ||
| N | n | % (95% CI) | OR (95% CI) | OR (95% CI) | |
| Total | 13 810 | 520 | 4 (3 to 4) | – | – |
| Sex | 0.001† | 0.204† | |||
| Men | 5839 | 278 | 5 (4 to 5) | Ref. | Ref. |
| Women | 7971 | 242 | 3 (3 to 3) | 0.63 (0.53 to 0.75) | 0.88 (0.72 to 1.07) |
| Age group | <0.001† | <0.001† | |||
| 15–49 years | 2072 | 31 | 1 (1 to 2) | 0.40 (0.27 to 0.59) | 0.39 (0.26 to 0.60) |
| 50–59 years | 2050 | 65 | 3 (2 to 4) | 0.86 (0.63 to 1.17) | 0.88 (0.64 to 1.21) |
| 60–69 years | 3181 | 117 | 4 (3 to 4) | Ref. | Ref. |
| 70–79 years | 3656 | 170 | 5 (4 to 5) | 1.28 (1.00 to 1.62) | 1.28 (1.00 to 1.64) |
| 80+ years | 2851 | 137 | 5 (4 to 6) | 1.32 (1.03 to 1.70) | 1.45 (1.12 to 1.89) |
| Cancer site | <0.001† | <0.001† | |||
| Leukaemia‡ | 450 | 103 | 23 (19 to 27) | 10.49 (7.55 to 14.58) | 11.84 (8.49 to 16.51) |
| Renal | 356 | 46 | 13 (10 to 17) | 5.25 (3.53 to 7.78) | 5.60 (3.77 to 8.33) |
| Thyroid | 110 | 13 | 12 (7 to 19) | 4.74 (2.53 to 8.88) | 7.25 (3.80 to 13.82) |
| Liver | 103 | 11 | 11 (6 to 18) | 4.23 (2.16 to 8.27) | 4.42 (2.24 to 8.68) |
| Myeloma | 228 | 20 | 9 (6 to 13) | 3.40 (2.02 to 5.72) | 3.39 (2.01 to 5.70) |
| Gallbladder | 68 | 5 | 7 (3 to 16) | 2.81 (1.09 to 7.20) | 2.96 (1.15 to 7.62) |
| Mesothelioma | 75 | 4 | 5 (2 to 13) | 1.99 (0.71 to 5.61) | 1.88 (0.66 to 5.31) |
| Lymphoma | 698 | 33 | 5 (3 to 7) | 1.75 (1.14 to 2.69) | 2.10 (1.37 to 3.23) |
| Vulval | 73 | 3 | 4 (1 to 11) | 1.51 (0.46 to 4.94) | 1.70 (0.52 to 5.60) |
| Lung | 1875 | 77 | 4 (3 to 5) | 1.51 (1.08 to 2.12) | 1.49 (1.07 to 2.09) |
| Melanoma | 834 | 30 | 4 (3 to 5) | 1.32 (0.85 to 2.05) | 1.69 (1.09 to 2.64) |
| Bladder | 842 | 28 | 3 (2 to 5) | 1.22 (0.78 to 1.91) | 1.16 (0.74 to 1.82) |
| Colorectal | 2399 | 66 | 3 (2 to 3) | Ref. | Ref. |
| Stomach | 302 | 8 | 3 (1 to 5) | 0.96 (0.46 to 2.02) | 0.94 (0.45 to 1.99) |
| Ovarian | 394 | 10 | 3 (1 to 5) | 0.92 (0.47 to 1.81) | 1.11 (0.56 to 2.20) |
| Laryngeal | 121 | 3 | 2 (1 to 7) | 0.90 (0.28 to 2.90) | 0.96 (0.30 to 3.12) |
| Oropharyngeal | 213 | 5 | 2 (1 to 5) | 0.85 (0.34 to 2.13) | 1.05 (0.42 to 2.64) |
| Small Intestine | 53 | 1 | 2 (0.3 to 10) | 0.68 (0.09 to 4.99) | 0.72 (0.10 to 5.28) |
| Pancreatic | 370 | 6 | 2 (1 to 3) | 0.58 (0.25 to 1.35) | 0.59 (0.26 to 1.38) |
| Endometrial | 410 | 6 | 1 (1 to 3) | 0.52 (0.23 to 1.22) | 0.61 (0.26 to 1.43) |
| Testicular | 149 | 2 | 1 (0.4 to 5) | 0.48 (0.12 to 1.98) | 1.05 (0.25 to 4.43) |
| Breast | 2675 | 34 | 1 (1 to 2) | 0.46 (0.30 to 0.69) | 0.59 (0.38 to 0.91) |
| Sarcoma‡ | 106 | 1 | 0.9 (0.2 to 5) | 0.34 (0.05 to 2.45) | 0.43 (0.06 to 3.14) |
| Brain | 215 | 2 | 0.9 (0.3 to 3) | 0.33 (0.08 to 1.36) | 0.37 (0.09 to 1.54) |
| Oesophageal | 566 | 3 | 0.5 (0.2 to 2) | 0.19 (0.06 to 0.60) | 0.19 (0.06 to 0.60) |
| Cervical | 125 | 0 | 0 (0 to 3) | N/A | N/A |
*Adjusted for sex, age group and cancer site.
†Joint Wald test p value.
‡No information was available on leukaemia or sarcoma type.
N/A, not applicable.